<生产厂家价格>

苯磺酸氨氯地平

苯磺酸氨氯地平用途

Amlodipine苯磺酸盐是长效钙离子通道抑制剂。

苯磺酸氨氯地平名称

[ CAS 号 ]:
111470-99-6

[ 中文名 ]:
2[(2-氨基乙氧基)甲基]-4(2-氯苯基)-3-乙氧甲酰基-5-甲氧甲酰基-6-甲基-1,4-二氢吡啶苯磺酸盐

[ 英文名 ]:
Amlodipine besylate

[中文别名 ]:

苯磺酸氨氯地平

[英文别名 ]:

Amlodin
Norvasc
UNII:864V2Q084H
MFCD00887594
Amlodipine Besilate
Amlodipine besylate
AMLODIPINE BENZENESULFONATE

苯磺酸氨氯地平生物活性

[ 描述 ]:

Amlodipine苯磺酸盐是长效钙离子通道抑制剂。

[ 相关类别 ]:

信号通路 >> 跨膜转运 >> 钙通道

研究领域 >> 心血管疾病

[参考文献]

[1]. http://en.wikipedia.org/wiki/Amlodipine

[相关活性小分子]

苯磺酸氨氯地平物理化学性质

[ 密度 ]:
1.227g/cm3

[ 沸点 ]:
527.2ºC at 760 mmHg

[ 熔点 ]:
199-201°C

[ 分子式 ]:
C₂₆H₃₁ClN₂O₈S

[ 分子量 ]:
567.051

[ 闪点 ]:
272.6ºC

[ 精确质量 ]:
566.148987

[ PSA ]:
162.63000

[ LogP ]:
5.30950

[ 外观性状 ]:
白色粉末

[ 蒸汽压 ]:
3.34E-11mmHg at 25°C

[ 储存条件 ]:
Store at RT

[ 水溶解性 ]:
DMSO: 20 mg/mL

苯磺酸氨氯地平MSDS

详细MSDS(安全技术说明书)

苯磺酸氨氯地平毒性和生态

CHEMICAL IDENTIFICATION

RTECS NUMBER :: US7967700

CHEMICAL NAME :: 3,5-Pyridinedicarboxylic acid, 2-((2-aminoethoxy)methyl)-4-(2-chlorophenyl)- 1,4-dihydro-6-methyl-, 3-ethyl-5-methyl ester, monobenzenesulfonate

CAS REGISTRY NUMBER :: 111470-99-6

LAST UPDATED :: 199806

DATA ITEMS CITED :: 12

MOLECULAR FORMULA :: C20-H25-Cl-N2-O5.C6-H6-O3-S

MOLECULAR WEIGHT :: 567.10

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Unreported

SPECIES OBSERVED :: Human - woman

DOSE/DURATION :: 6 mg/kg/60D-I

TOXIC EFFECTS :: Sense Organs and Special Senses (Olfaction) - effect, not otherwise specified

REFERENCE :: LANCAO Lancet. (7 Adam St., London WC2N 6AD, UK) V.1- 1823- Volume(issue)/page/year: 341,1102,1993

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 393 mg/kg

TOXIC EFFECTS :: Sense Organs and Special Senses (Eye) - ptosis Lungs, Thorax, or Respiration - respiratory depression Blood - other changes

REFERENCE :: OYYAA2 Oyo Yakuri. Pharmacometrics. (Oyo Yakuri Kenkyukai, CPO Box 180, Sendai 980-91, Japan) V.1- 1967- Volume(issue)/page/year: 42,177,1991

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intraperitoneal

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 42 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: NIIRDN Drugs in Japan (Ethical Drugs). (Yakugyo Jiho Co., Ltd., Tokyo, Japan) Volume(issue)/page/year: -,71,1995

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Subcutaneous

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 678 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: NIIRDN Drugs in Japan (Ethical Drugs). (Yakugyo Jiho Co., Ltd., Tokyo, Japan) Volume(issue)/page/year: -,71,1995

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 37 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: NIIRDN Drugs in Japan (Ethical Drugs). (Yakugyo Jiho Co., Ltd., Tokyo, Japan) Volume(issue)/page/year: -,71,1995

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intraperitoneal

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 31 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: NIIRDN Drugs in Japan (Ethical Drugs). (Yakugyo Jiho Co., Ltd., Tokyo, Japan) Volume(issue)/page/year: -,71,1995

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Subcutaneous

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 36 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: NIIRDN Drugs in Japan (Ethical Drugs). (Yakugyo Jiho Co., Ltd., Tokyo, Japan) Volume(issue)/page/year: -,71,1995 ** OTHER MULTIPLE DOSE TOXICITY DATA **

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 910 mg/kg/13W-C

TOXIC EFFECTS :: Kidney, Ureter, Bladder - urine volume increased Kidney, Ureter, Bladder - other changes in urine composition

REFERENCE :: OYYAA2 Oyo Yakuri. Pharmacometrics. (Oyo Yakuri Kenkyukai, CPO Box 180, Sendai 980-91, Japan) V.1- 1967- Volume(issue)/page/year: 42,177,1991

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 36400 mg/kg/52W-C

TOXIC EFFECTS :: Kidney, Ureter, Bladder - urine volume increased Kidney, Ureter, Bladder - other changes in urine composition Related to Chronic Data - death

REFERENCE :: OYYAA2 Oyo Yakuri. Pharmacometrics. (Oyo Yakuri Kenkyukai, CPO Box 180, Sendai 980-91, Japan) V.1- 1967- Volume(issue)/page/year: 42,177,1991 ** REPRODUCTIVE DATA **

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 2300 mg/kg

SEX/DURATION :: male 71 day(s) pre-mating female 2 week(s) pre-mating - 7 day(s) after conception

TOXIC EFFECTS :: Reproductive - Fertility - pre-implantation mortality (e.g. reduction in number of implants per female; total number of implants per corpora lutea) Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus)

REFERENCE :: OYYAA2 Oyo Yakuri. Pharmacometrics. (Oyo Yakuri Kenkyukai, CPO Box 180, Sendai 980-91, Japan) V.1- 1967- Volume(issue)/page/year: 42,167,1991

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 275 mg/kg

SEX/DURATION :: female 7-17 day(s) after conception

TOXIC EFFECTS :: Reproductive - Effects on Newborn - viability index (e.g., # alive at day 4 per # born alive)

REFERENCE :: OYYAA2 Oyo Yakuri. Pharmacometrics. (Oyo Yakuri Kenkyukai, CPO Box 180, Sendai 980-91, Japan) V.1- 1967- Volume(issue)/page/year: 42,167,1991

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 260 mg/kg

SEX/DURATION :: female 17-21 day(s) after conception lactating female 21 day(s) post-birth

TOXIC EFFECTS :: Reproductive - Maternal Effects - parturition Reproductive - Effects on Newborn - live birth index (measured after birth) Reproductive - Effects on Newborn - viability index (e.g., # alive at day 4 per # born alive)

REFERENCE :: OYYAA2 Oyo Yakuri. Pharmacometrics. (Oyo Yakuri Kenkyukai, CPO Box 180, Sendai 980-91, Japan) V.1- 1967- Volume(issue)/page/year: 42,167,1991

苯磺酸氨氯地平安全信息

[ 符号 ]:

GHS07

[ 信号词 ]:
Warning

[ 危害声明 ]:
H302

[ 警示性声明 ]:
P301 + P312 + P330

[ 个人防护装备 ]:
dust mask type N95 (US);Eyeshields;Faceshields;Gloves

[ 危害码 (欧洲) ]:
Xn: Harmful;

[ 风险声明 (欧洲) ]:
R22

[ 安全声明 (欧洲) ]:
26-36

[ 危险品运输编码 ]:
NONH for all modes of transport

[ WGK德国 ]:
3

[ RTECS号 ]:
US7967700

[ 海关编码 ]:
2933990090

苯磺酸氨氯地平合成路线

详细合成路线

苯磺酸氨氯地平上下游产品

苯磺酸氨氯地平上游产品

苯磺酸氨氯地平下游产品

苯磺酸氨氯地平制备

1. N-(2-羟乙基)邻苯二甲酸亚酰胺的制备

在反应瓶中加入邻苯二甲酸酐14.8g(0.1mol)和DMF100ml,搅拌升温至50ºC,滴加乙醇胺6.1g(0.1mol)滴毕,升温至95ºC搅拌反应6h.冷却,过滤,水洗,干燥,得白色晶体N-(2-羟乙基)邻苯二甲酸亚酰胺17.6g,收率95.3%mp126.8~128.0ºC.

2. 4-[(2-邻苯二甲酰亚胺)乙氧基]乙酰乙酸乙酯的制备

在反应瓶中加入N-(2-羟乙基)邻苯二甲酸亚酰胺19.5g(0.1mol)和THF60ml,搅拌溶解,降温至10ºC以下#加入NaH8g(0.2mol)搅拌30min.缓慢加入4-氯乙酰乙酸乙酯16.5g(0.1mol),加毕#逐渐升温至40ºC,TLC跟踪反应终点.用冷却的2mol/L盐酸调反应液pH6~7,静置,分出水相,常压蒸出THF回收,用乙酸乙酯(30ml×2)提取,合并提取液和有机相,饱和食盐水洗,无水MgSO4干燥,减压浓缩,得黄色油状物4-[(2-邻苯二甲酰亚胺)乙氧基]乙酰乙酸乙酯32.2g,收率75.8%,含量>75%(HPLC法).

3. 3-氨基-4-[(2-邻苯二甲酰亚胺)乙氧基]-2-丁烯酸乙酯的制备

在反应瓶中加入4-[(2-邻苯二甲酰亚胺)乙氧基]乙酰乙酸乙酯38.3g(90mmol)、乙酸铵8g(0.1mol)、乙醇80ml,搅拌回流反应1h.浓缩回收乙醇,浓缩物加乙酸乙酯100ml溶解,水(60ml×2)洗,减压蒸馏,得浅黄色液体3-氨基-4-[(2-邻苯二甲酰亚胺)乙氧基]-2-丁烯酸乙酯34.7g,收率90.1%,含量>75%(HPLC法).

4. 4-[(2-氯苯基)-3-乙氧羰基]-5-甲氧羰基-6-甲基-2-(2-邻苯二甲酰亚胺)甲基-1,4-二氯吡啶的制备

在反应瓶中加入3-氨基-4-[(2-邻苯二甲酰亚胺)乙氧基]-2-丁烯酸乙酯42.4g(0.1mol)、2-乙氧羰基-3-(2-氯苯基)丙烯酸甲酯23.9g(0.1mol)和乙酸200ml,搅拌回流20h.冷却,得黄色油状物,静置冷却,析出结晶,过滤,干燥,得白色晶体4-[(2-氯苯基)-3-乙氧羰基]-5-甲氧羰基-6-甲基-2-(2-邻苯二甲酰亚胺)甲基-1,4-二氯吡啶53.9g,收率74.5%,mp145~147ºC.

5. 2-[(2-氨基乙氧基)甲基]-4-(2-氯苯基)-3-乙氧羰基-5-甲氧羰基-6-甲基-1,4-二氢吡啶(氨氯地平)的制备

在反应瓶中加入乙醇150ml、4-[(2-氯苯基)-3-乙氧羰基]-5-甲氧羰基-6-甲基-2-(2-邻苯二甲酰亚胺)甲基-1,4-二氯吡啶53.8g(0.10mol)、17mol/L水合肼7.0ml,搅拌回流3h.冷却,过滤,乙酸乙酯重结晶,干燥,得浅黄色固体2-[(2-氨基乙氧基)甲基]-4-(2-氯苯基)-3-乙氧羰基-5-甲氧羰基-6-甲基-1,4-二氢吡啶(氨氯地平)38g,收率93%,mp177~179ºC.

6. 苯磺酸氨氯地平的合成

在反应瓶中加入无水乙醇150ml和2-[(2-氨基乙氧基)甲基]-4-(2-氯苯基)-3-乙氧羰基-5-甲氧羰基-6-甲基-1,4-二氢吡啶(氨氯地平)40.9g(0.1mol),搅拌降温至15 ºC以下,加入苯磺酸19.8g(0.125mol),于室温搅拌5h.过滤,滤饼用乙醇洗,干燥,得苯磺酸氨氯地平52.4g,收率92.5%,mp199~201ºC,含量≥99.0%(HPLC法).

苯磺酸氨氯地平海关

[ 海关编码 ]: 2933990090

[ 中文概述 ]:
2933990090. 其他仅含氮杂原子的杂环化合物. 增值税率:17.0%. 退税率:13.0%. 监管条件:无. 最惠国关税:6.5%. 普通关税:20.0%

[ 申报要素 ]: 品名, 成分含量, 用途, 乌洛托品请注明外观, 6－己内酰胺请注明外观, 签约日期

[ Summary ]:
2933990090. heterocyclic compounds with nitrogen hetero-atom(s) only. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%

苯磺酸氨氯地平文献

Drug effects on the CVS in conscious rats: separating cardiac output into heart rate and stroke volume using PKPD modelling.

Br. J. Pharmacol. 171(22) , 5076-92, (2014)

Previously, a systems pharmacology model was developed characterizing drug effects on the interrelationship between mean arterial pressure (MAP), cardiac output (CO) and total peripheral resistance (T...

[Hypertension. Goal: achieving target blood pressure with only 1 pill daily].

MMW Fortschr. Med. 155(6) , 66-7, (2013)

Comparative study between derivative spectrophotometry and multivariate calibration as analytical tools applied for the simultaneous quantitation of Amlodipine, Valsartan and Hydrochlorothiazide.

Spectrochim. Acta. A. Mol. Biomol. Spectrosc. 113 , 215-23, (2013)

Four simple, accurate and specific methods were developed and validated for the simultaneous estimation of Amlodipine (AML), Valsartan (VAL) and Hydrochlorothiazide (HCT) in commercial tablets. The de...

更多文献

苯磺酸氨氯地平相关知识

【苯磺酸氨氯地平】-说明书-作用-苯磺酸氨氯地平片副作用

2018-12-24 17:57:26

导读：苯磺酸氨氯地平，商品名络活喜、苯磺酸氨氯地平片。1.高血压（单独或与其他药物合并使用）。 2.心绞痛：尤其自发性心绞痛（单独或与其他药物合并使用）。本药品被归类到心绞痛等药品分类。【药品名称】通用名称：苯磺酸氨氯地平片商品名称：苯磺酸氨氯地平片(络活喜) 英文名称：Amlodipi...